Atherosclerosis
Volume 168, Issue 2 , Pages 375-380 , June 2003

Effect of xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease

  • Shui-Ping Zhao

      Affiliations

    • Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China
    • ,
  • Ling Liu

      Affiliations

    • Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China
    • Corresponding Author InformationCorresponding author. Tel.: +86-731-885-6433; fax: +86-731-489-5989
    • ,
  • Yan-Chun Cheng

      Affiliations

    • Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China
    • ,
  • Yu-Ling Li

      Affiliations

    • Department of Nutrition, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China

Received 1 July 2002 ,Revised 14 January 2003 ,Accepted 26 March 2003.

References 

  1. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary heart disease in young male postinfarction patients. Lancet. 1996;347:849–853
  2. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridaemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am. J. Cardiol. 1996;77:1179–1184
  3. The Munster Heart Study (PROCAM) Assmann G, Cullen P, Schulte H. Results of follow-up at 8 years. Eur. Heart J. 1998;19(Suppl. A):A2–A11
  4. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk. 1996;3:213–219
  5. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60:473–485
  6. Groot PH, van Stiphout WA, Krauss XH, Jansen H, Vantol A, Van Ramshorst E, et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler. Thromb. 1991;11:653–662
  7. Weintraub MS, Grosskopf I, Rassin T, Miller H, Charach G, Rotmensch HH, et al. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over 3 years. Br. Med. J. 1996;312:936–939
  8. Slyper AH. A fresh look at the atherogenic remnant hypothesis. Lancet. 1992;340:289–291
  9. Doi H, Kugiyama K, Ohgushi M, Sugiyama S, Matsumura T, Ohta Y, et al. Remnants of chylomicron and very low density lipoprotein impair endothelium-dependent vasorelaxation. Atherosclerosis. 1998;137:341–349
  10. Grieve DJ, Avella MA, Elliott J, Botham KM. The influence of chylomicron remnants on endothelial cell function in the isolated perfused rat aorta. Atherosclerosis. 1998;139:273–281
  11. Patsch JR, Miesenbock G, Hopferwieser T, Mühlberger V, Knapp E, Dunn JK, et al. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler. Thromb. 1992;12:1336–1345
  12. Silveira A, Karpe F, Blomback M, Steiner G, Walldius G, Hamsten A. Activation of coagulation factor VII during alimentary lipemia. Arterioscler. Thromb. 1994;14:60–69
  13. Zhao SP, Liu L, Gao M, Zhou QC, Li YL, Xia B. Impairment of endothelial function after a high-fat meal in patients with coronary artery disease. Coron. Artery Dis. 2001;12:561–565
  14. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am. J. Cardiol. 2000;86:943–949
  15. Sheu WH, Jeng CY, Lee WJ, Lin SY, Pei D, Chen YT. Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia. Metabolism. 2000;50:355–359
  16. Battula SB, Fitzsimons O, Moreno S, Owens D, Collins P, Johnson A, et al. Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism. Metabolism. 2000;49:1049–1054
  17. Isusi E, Aspichueta P, Liza M, Hernandez ML, Diaz C, Hernandez G, et al. Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes. Atherosclerosis. 2000;153:283–294
  18. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am. J. Clin. Nutr. 1999;69:231–236
  19. Kou WR, Lu ZL, Guo JX, Li HY, Xue SW, Lin YZ, et al. Effect of xuezhikang on the treatment of primary hyperlipidemia. Zhonghua Nei Ke Za Zhi. 1997;36:529–531
  20. Jian JB, Hao XY, Deng CQ, Zhou HT, Lin J. The effects of Xuezhikang on serum lipid profile, thromboxane A(2) and prostacyclin in patients with hyperlipoidemia. Zhonghua Nei Ke Za Zhi. 1999;38:517–519
  21. Keithley JK, Swanson B, Sha BE, Zeller JM, Kessler HA, Smith KY. A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia. Nutrition. 2002;18:201–204
  22. Vigna GB, Donega P, Passaro A, Zanca R, Cattin L, Fonda M, et al. Effects of fibric acid derivatives and metformin on postprandial lipemia. Atherosclerosis. 1998;141(Suppl. 1):S71–S75
  23. Vigna GB, Donega P, Passaro A, Zanca R, Cattin L, Fonda M, et al. Post-prandial effects of gemfibrozil vs. simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia. Nutr. Metab. Cardiovasc. Dis. 1999;9:234–243
  24. O'Keefe JH, Harris WS, Nelson J, Windsor SL. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am. J. Cardiol. 1995;76:480–484
  25. Westphal S, Orth M, Ambrosch A, Osmundsen K, Luley C. Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids. Am. J. Clin. Nutr. 2000;71:914–920
  26. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). Perfusion. 1998;11:202–208
  27. Weintraub MS, Eisenberg S, Breslow JL. Lovastatin reduces postprandial lipoprotein levels in hypercholesterolaemic patients with mild hypertriglyceridaemia. Eur. J. Clin. Invest. 1989;19:480–485
  28. Simo IE, Yakichuk JA, Ooi TC. Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome. Atherosclerosis. 1993;100:55–64
  29. Stein EA, Lane M, Laskarrzewski P. Comparison of statins in typertriglyceridmia. Am. J. Cardiol. 1998;81:B66–B69

PII: S0021-9150(03)00142-4

doi: 10.1016/S0021-9150(03)00142-4

Atherosclerosis
Volume 168, Issue 2 , Pages 375-380 , June 2003

Article Tools

* Image Usage & Resolution